Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIR9900 for VEXAS syndrome
ACTRN12626001126303Phase 2Not yet recruiting
- Sponsor
- Sironax
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of SIR9900 in VEXAS syndrome (VEXAS) (3 arms), sponsored by Sironax. Primary endpoint: Proportion of participants achieving Overall Clinical Response (clinical response or better). Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SIR9900
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on ACTRN12626001126303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001126303.